Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Sells $128,712.24 in Stock

Key Points

• Amylyx Pharmaceuticals insider Gina Mazzariello sold 8,828 shares for approximately $128,712.24, reducing her ownership by 5.62% to about 148,141 shares.
• The company's stock price fell 5.1% to $13.29, with a recent trading volume significantly above its average, and it has a market cap of $1.19 billion.
• Amylyx Pharmaceuticals reported a quarterly loss of ($0.46) EPS, missing estimates, while analysts maintain a consensus rating of "Buy" with a target price around $14.50.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Gina Mazzariello sold 8,828 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $14.58, for a total transaction of $128,712.24. Following the sale, the insider owned 148,141 shares in the company, valued at approximately $2,159,895.78. This represents a 5.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amylyx Pharmaceuticals Stock Down 5.1%

NASDAQ AMLX traded down $0.71 on Thursday, hitting $13.29. The company's stock had a trading volume of 3,330,605 shares, compared to its average volume of 1,254,741. The company's 50-day moving average is $10.09 and its 200 day moving average is $6.87. The firm has a market cap of $1.19 billion, a PE ratio of -5.32 and a beta of -0.34. Amylyx Pharmaceuticals, Inc. has a 1-year low of $2.60 and a 1-year high of $15.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.02). On average, equities analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on AMLX shares. Wall Street Zen upgraded Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday, July 18th. Guggenheim upped their price objective on shares of Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, September 15th. Jefferies Financial Group initiated coverage on shares of Amylyx Pharmaceuticals in a research report on Tuesday, June 24th. They set a "hold" rating for the company. The Goldman Sachs Group lifted their target price on shares of Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, September 16th. Finally, Citigroup began coverage on shares of Amylyx Pharmaceuticals in a research report on Tuesday, June 17th. They set a "buy" rating and a $12.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $14.50.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. grew its holdings in shares of Amylyx Pharmaceuticals by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company's stock valued at $56,408,000 after buying an additional 3,102,395 shares during the last quarter. Perceptive Advisors LLC lifted its position in Amylyx Pharmaceuticals by 0.4% in the 2nd quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company's stock valued at $50,654,000 after acquiring an additional 28,017 shares in the last quarter. Saturn V Capital Management LP boosted its stake in Amylyx Pharmaceuticals by 34.4% during the 2nd quarter. Saturn V Capital Management LP now owns 3,260,570 shares of the company's stock valued at $20,900,000 after purchasing an additional 834,134 shares during the last quarter. Millennium Management LLC increased its holdings in Amylyx Pharmaceuticals by 418.6% during the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company's stock worth $10,910,000 after purchasing an additional 2,487,617 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its holdings in Amylyx Pharmaceuticals by 102.1% during the 1st quarter. Nantahala Capital Management LLC now owns 2,934,405 shares of the company's stock worth $10,388,000 after purchasing an additional 1,482,252 shares in the last quarter. Institutional investors and hedge funds own 95.84% of the company's stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.